Aiolos activators comprise a diverse class of chemicals that exert their influence on the transcription factor Aiolos, a member of the Ikaros family involved in B-cell differentiation and immune responses. While direct activators of Aiolos remain limited, several compounds indirectly modulate its activity through various mechanisms. One prominent group of Aiolos activators includes BET bromodomain inhibitors such as PRT4165 and INCB057643. These compounds impact Aiolos by targeting bromodomain and extraterminal (BET) proteins, altering chromatin accessibility and facilitating Aiolos transcription. By disrupting the interactions between BET proteins and acetylated histones, these inhibitors can potentially enhance Aiolos expression, influencing B-cell differentiation and immune responses.
Another set of Aiolos activators involves compounds like CC-122 and CC-90005, which indirectly regulate Aiolos by targeting cereblon and lysine-specific demethylase 1 (LSD1), respectively. CC-122 influences the degradation of Aiolos through its impact on cereblon, while CC-90005 alters histone modifications, potentially facilitating Aiolos transcription. These indirect activation mechanisms showcase the intricate connections between cellular processes, epigenetic regulation, and Aiolos expression. Furthermore, kinase inhibitors like Cerdulatinib, GS-9973, and Ibrutinib indirectly activate Aiolos by modulating signaling pathways associated with SYK, JAK, and BTK kinases, respectively. Through inhibition of these kinases, these compounds influence downstream events that can impact Aiolos expression, highlighting the complex interplay between kinase signaling and Aiolos regulation in immune cells. In summary, Aiolos activators represent a multifaceted group of chemicals that modulate Aiolos activity through diverse mechanisms, including epigenetic regulation, kinase signaling, and protein-protein interactions. Understanding the detailed biochemical and cellular pathways through which these activators operate provides valuable insights into the regulation of Aiolos and its crucial role in immune cell function and differentiation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PRT4165 | 31083-55-3 | sc-507487 | 10 mg | $134.00 | ||
PRT4165, a BET bromodomain inhibitor, indirectly activates Aiolos by modulating epigenetic regulation. Inhibition of BET bromodomains alters chromatin accessibility, potentially facilitating Aiolos transcription. This indirect activation highlights the connection between epigenetic regulation and Aiolos expression, influencing B-cell differentiation and immune responses. | ||||||
CC-122 | 1015474-32-4 | sc-507488 | 5 mg | $420.00 | ||
CC-122, an immunomodulatory compound, indirectly activates Aiolos by targeting cereblon. Modulation of cereblon by CC-122 influences the degradation of Aiolos, affecting its protein levels. This indirect activation emphasizes the interplay between CC-122, cereblon, and Aiolos, contributing to the regulation of immune responses and inflammatory processes. | ||||||
GS 9973 | 1229208-44-9 | sc-490337 sc-490337A sc-490337B sc-490337C sc-490337D | 10 mg 50 mg 100 mg 500 mg 1 g | $250.00 $878.00 $1353.00 $5500.00 $9000.00 | ||
GS-9973, a SYK kinase inhibitor, indirectly activates Aiolos by modulating signaling pathways. Inhibition of SYK kinase by GS-9973 influences downstream events, potentially impacting Aiolos expression. This indirect activation highlights the complex interplay between SYK kinase signaling and Aiolos regulation, affecting immune cell function and inflammatory responses. | ||||||
CPI-0610 | 1380087-89-7 | sc-507490 | 10 mg | $495.00 | ||
CPI-0610, an LSD1 inhibitor, indirectly activates Aiolos through epigenetic regulation. Inhibition of LSD1 alters histone modifications, potentially facilitating Aiolos transcription. This indirect activation underscores the connection between LSD1, histone modifications, and Aiolos expression, impacting B-cell differentiation and immune responses. | ||||||